JPRN-jRCT2080221499
Unknown
Phase 2
Prevention of Recurrent Gastric or Duodenal Ulcers caused by Low-dose Aspirin with Rabeprazole (E3810) Treatment. -A Multicenter, Randomized, Parallel-group, Double-blind Comparative Trial-(Planetarium study)
Overview
- Phase
- Phase 2
- Sponsor
- Eisai Co., Ltd.
- Enrollment
- 450
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 20age old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- •Require long\-term administration of low\-dose aspirin (81 mg/day or 100 mg/day).
- •Confirmed to have a history of gastric or duodenal ulcer.
Exclusion Criteria
- •Confirmed to have acute gastroduodenal mucosal lesions, gastric or duodenal ulcer, or upper gastrointestinal (esophagus, stomach, duodenum) bleeding.
- •Confirmed to have reflux esophagitis or long segment Barrett's esophagus.
Investigators
Similar Trials
Completed
Phase 2
Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)Gastric or Duodenal Ulcers Caused by Low-dose AspirinNCT01397448Eisai Co., Ltd.472
Unknown
Phase 2
ong-term administration study of E3810 for the prevention of gastric or duodenal ulcer caused by low-dose aspiriJPRN-jRCT2080221500Eisai Co., Ltd.300
Recruiting
Phase 4
Prevention of Recurrent Ulcer Bleeding in Patients With Idiopathic Gastroduodenal UlcerActive Peptic Ulcer Disease/GI BleedingNCT03675672Chinese University of Hong Kong154
Active, not recruiting
Phase 1
Prevention of oesophagitis, gastric and duodenal lesions in patients taking antithrombotic low-dose aspirin with famotidineEUCTR2005-004849-33-GBHS Greater Glasgow700
Recruiting
Not Applicable
Prevention of gastrointestinal complications by infusion pump in patients receiving enteral nutritioInpatients receiving enteral nutrition via nasogastric tube, gastric fistula, or intestinal fistulaJPRN-UMIN000005609Division of Clinical pharmacokinetics, Faculty of Pharmacy, Keio University200